TILT Biotherapeutics Ltd. logo

TILT Biotherapeutics Ltd.

TILT Biotherapeutics is a cancer immunotherapy company, develops genetically modified oncolytic viruses that enhance T-cell therapies for cancer treatment. The company uses the T-cell therapy to extract T-cells from cancer patients which are then grown at the lab outside of patients body, and finally transferred back to the same patient along with genetically modified virus injected into the tumor and blood circulation.

0
Management
0
Technology
0
Deals/Partnering
0
Research Pipeline
0
Funding
BioStartup's Score 0 / 50

KEY DETAILS

Websitehttp://tiltbio.com
Founded2013
Disease Focus
Development Stage
STOCK CODENon Listed
Address
Haartmaninkatu 3, 4th floor, C-wing 00290
Helsinki
Finland
Email
Contact Number
+358 9191 25464

TILT Biotherapeutics is a cancer immunotherapy company, develops genetically modified oncolytic viruses that enhance T-cell therapies for cancer treatment. The company uses the T-cell therapy to extract T-cells from cancer patients which are then grown at the lab outside of patients body, and finally transferred back to the same patient along with genetically modified virus injected into the tumor and blood circulation.

TILT was founded by Pr. Akseli Hemminki, who has published hundreds of papers in the field and treated almost 300 patients with 10 different oncolytic viruses.

[atom_linkedin linkedin_option=”CompanyInsider” linkedin_id=”https://in.linkedin.com/company/tilt-biotherapeutics-ltd” connections=”true” suffix=””]

The companys patented technology involves utilization of oncolytic viruses for enhancement of tumor T-cell therapy. Initial embodiments of the technology will be used to enhance tumor infiltrating lymphocyte (TIL), chimeric antigen receptor (CAR-T) and checkpoint inhibiting antibody therapy.

In Dec 2016, TILT Biotherapeutics closed a financing round of 4.0MnÑ (~$4.3Mn) to progress its lead candidate, TILT-123, into Ph I clinical trials. This adds up to TILTs seed funding, bringing its total funding to almost 10MnÑ (~$10.6Mn).
TILTs investors include Lifeline Ventures Ltd, the Finnish Funding Agency for Technology and Innovation (Tekes), the European Commission, and business angels.